Clinical Trial Update: DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial called DISCERN is evaluating dual versus single immune checkpoint blockade in PD-L1 negative non-small cell lung cancer. The study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING